QTREX Quantum Ltd. (QTEX) stock
Close on Nov 12, 2026Market cap $42.78MP/E –Yield –
QTREX Quantum Ltd. reported revenue of $289.00K for fiscal 2025. Free cash flow was -$9.96M. At the latest close the market valued the company at $42.78M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $42.78M
- P/E ratio
- –
- Price to sales
- 148.03
- Price to book
- 3.98
- Dividend yield
- –
- Free cash flow yield
- -23.29%
Fundamentals
- Revenue
- $289.00K
- Net income
- -$13.22M
- EPS, diluted
- -$0.45
- Free cash flow
- -$9.96M
Trading
- Previous close
- $0.98
- Open
- $1.08
- Day's range
- $0.99 – $1.20
- Volume
- 8,048,805
- Average volume (20 days)
- 4,287,437
- Beta (5 years)
- 2.53
- 52-week range
- $0.28 – $3.85
- RSI (14 days)
- 50.4
- Volatility (1 year)
- 233.6%
- Relative volume
- 1.08×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | QTEX | S&P 500 | Difference | QTEX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.7% | -2.7% | −22.0 pts | ||
| 3 months | +17.8% | -1.7% | +19.6 pts | ||
| Year to date | +32.2% | +11.9% | +20.3 pts | ||
| 1 year | +21.4% | +12.0% | +9.4 pts | ||
| 3 years | -2.5% | +78.2% | −80.6 pts | -0.8% | +21.2% |
| 5 years | -68.1% | +73.2% | −141.3 pts | -20.4% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases QTREX Quantum filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About QTREX Quantum
Surgical & Medical Instruments & Apparatus
Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company that develops, manufactures, and commercializes proprietary life-support technologies. Its development efforts target acute respiratory failure solutions designed to offer alternatives or complementary options to traditional mechanical ventilation by enabling spontaneous breathing and reducing the need for invasive intubation or medically induced comas. The company's pipeline includes the flagship INSPIRA ART platform for extracorporeal blood oxygenation and monitoring, the FDA-cleared INSPIRA ART100 cardiopulmonary bypass system for surgical procedures, and the HYLA blood sensor for continuous real-time blood parameter analysis. The company targets healthcare providers across intensive care units, general medical units, operating theaters, and emergency settings.
Company profile, executives and historyQTREX Quantum stock: common questions
What is QTREX Quantum's stock price?
QTEX closed at $1.19 on Nov 12, 2026, up 21.12% on the day. Over the past 52 weeks it traded between $0.28 and $3.85.
What is QTREX Quantum's market cap?
QTREX Quantum was worth $42.78M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is QTEX's P/E ratio?
QTREX Quantum lost money over fiscal 2025 (diluted EPS -$0.45), so it has no meaningful P/E ratio.
How much revenue does QTREX Quantum make?
QTREX Quantum reported revenue of $289.00K for fiscal 2025.
Does QTREX Quantum pay a dividend?
No. QTREX Quantum has not paid a cash dividend over the last twelve months.
How has QTEX stock performed over the past year?
Including dividends, QTEX returned +21.4% over the past year, against +12.0% for the S&P 500.
How many QTEX shares are sold short?
4M shares were sold short at the latest FINRA report, 13.79% of the float, or 1.0 days of average trading volume.
Who are QTREX Quantum's competitors?
Companies most similar to QTREX Quantum by business, industry and size include GUTS, PAVM, ICU, HRGN, RDGL.
See a number that looks wrong?